CO6321269A2 - Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta 2 para el tratamiento de transtornos respiratorios - Google Patents

Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta 2 para el tratamiento de transtornos respiratorios

Info

Publication number
CO6321269A2
CO6321269A2 CO10150418A CO10150418A CO6321269A2 CO 6321269 A2 CO6321269 A2 CO 6321269A2 CO 10150418 A CO10150418 A CO 10150418A CO 10150418 A CO10150418 A CO 10150418A CO 6321269 A2 CO6321269 A2 CO 6321269A2
Authority
CO
Colombia
Prior art keywords
beta
treatment
respiratory disorders
derivatives acting
benzoxazinone derivatives
Prior art date
Application number
CO10150418A
Other languages
English (en)
Inventor
Roger Victor Bonnert
Stephen Connolly
Antony Ronald Cook
Richard Livesey Evans
Piotr Raubo
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO6321269A2 publication Critical patent/CO6321269A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1.- Un compuesto de fórmula (I):en el que:W es CH2 sustituido con 0, 1 ó 2 grupos CH3;R1 es ciclopentilo, ciclohexilo, cicloheptilo o CH(CH3)(alquilo C1-6);R2 es un heteroarilo de 5 miembros que contiene nitrógeno que posee opcionalmente un átomo de oxígeno en el anillo, y R2 es un alquilo C1-6 opcionalmente sustituido (a su vez opcionalmente sustituido con alcoxi C1-6 o cicloalquilo C3-6);R3 es hidrógeno, halógeno, alquilo C1-4, CF3, alcoxi C1-4, OCF3 o ciano;o una sal farmacéuticamente aceptable de este.
CO10150418A 2008-06-18 2010-11-29 Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta 2 para el tratamiento de transtornos respiratorios CO6321269A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7342008P 2008-06-18 2008-06-18

Publications (1)

Publication Number Publication Date
CO6321269A2 true CO6321269A2 (es) 2011-09-20

Family

ID=41434296

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10150418A CO6321269A2 (es) 2008-06-18 2010-11-29 Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta 2 para el tratamiento de transtornos respiratorios

Country Status (21)

Country Link
US (1) US8017602B2 (es)
EP (1) EP2303873A4 (es)
JP (1) JP2011524896A (es)
KR (1) KR20110017456A (es)
CN (1) CN102124003A (es)
AR (1) AR072189A1 (es)
AU (1) AU2009260899B2 (es)
BR (1) BRPI0915428A2 (es)
CA (1) CA2726746A1 (es)
CL (1) CL2010001459A1 (es)
CO (1) CO6321269A2 (es)
CR (1) CR11856A (es)
DO (1) DOP2010000389A (es)
EA (1) EA201001747A1 (es)
EC (1) ECSP10010694A (es)
IL (1) IL209731A0 (es)
MX (1) MX2010013477A (es)
TW (1) TW201002696A (es)
UY (1) UY31905A (es)
WO (1) WO2009154557A1 (es)
ZA (1) ZA201008886B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011524896A (ja) 2008-06-18 2011-09-08 アストラゼネカ・アクチエボラーグ 呼吸器障害の処置用のベータ２−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
CN102993116A (zh) * 2012-12-04 2013-03-27 常州大学 一种苯并噁嗪类激动剂的制备方法
HUE042370T2 (hu) * 2014-06-30 2019-06-28 Astrazeneca Ab Benzoxazinon-amidok mint mineralokortikoid-receptor modulátorok
CN104496920A (zh) * 2014-12-04 2015-04-08 北京理工大学 一种n-烯丙基-二取代四唑及其制备方法和检测方法
CN107188865B (zh) * 2016-03-14 2019-08-27 益方生物科技（上海）有限公司 苯并噁嗪化合物及其制备方法和用途
PL424609A1 (pl) * 2018-02-16 2019-08-26 Uniwersytet Przyrodniczy we Wrocławiu Zastosowanie 6-(tert-butylo)-3-dodecylo-3,4-dihydro-2H-benzo[e][1,3]oxazyny
CN110028521B (zh) * 2019-05-27 2020-07-14 湖南科技大学 11-芳基-1,4-苯并恶嗪酮并咪唑啉类化合物及其制备方法和用途
EP4194453A1 (en) 2021-12-08 2023-06-14 Basf Se Pyrazine compounds for the control of invertebrate pests
WO2023104564A1 (en) 2021-12-08 2023-06-15 Basf Se Pyrazine compounds for the control of invertebrate pests

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2653977A (en) 1953-09-29 Chxnx
US3775477A (en) 1971-03-10 1973-11-27 Sterling Drug Inc N,n'-bis(2-aryl-2-(hydroxy or oxo)-ethyl)-bridged-bis-carboxamides
US4460581A (en) 1982-10-12 1984-07-17 Boehringer Ingelheim Kg (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones
DE3571808D1 (en) 1984-04-17 1989-08-31 Glaxo Group Ltd Ethanolamine compounds
US4554287A (en) 1984-09-12 1985-11-19 Smithkline Beckman Corporation Antihypertensive 7-[2-(dialkylamino)ethyl]-4-hydroxy-1,3-benzimidazol-2-ones
US4554284A (en) 1984-09-12 1985-11-19 Smithkline Beckman Corporation 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
GB8525483D0 (en) 1985-10-16 1985-11-20 Glaxo Group Ltd Chemical compounds
GB8718938D0 (en) 1987-08-11 1987-09-16 Glaxo Group Ltd Chemical compounds
PT95542B (pt) 1989-10-10 1999-09-30 Glaxo Group Ltd Processo para a prparacao de derivados de fenetanolamina
IE914003A1 (en) 1990-11-20 1992-05-20 Astra Pharma Prod Biologically Active Amines
GB9210632D0 (en) 1992-05-19 1992-07-01 Fisons Plc Compounds
GB9211172D0 (en) 1992-05-27 1992-07-08 Fisons Plc Compounds
US5648370A (en) 1990-11-20 1997-07-15 Astra Pharmaceuticals Limited 7-(2-aminoethyl) benzothiazolones
TW356468B (en) 1995-09-15 1999-04-21 Astra Pharma Prod Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
GB9526511D0 (en) 1995-12-23 1996-02-28 Astra Pharma Prod Pharmaceutically active compounds
DE69709647T2 (de) 1996-05-20 2002-11-07 Dupont Pharmaceuticals Research Laboratories, Inc. Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren
SE9700706D0 (sv) 1997-02-27 1997-02-27 Astra Pharma Prod Process for the preparation of benzothiazoline compounds
SE9701304D0 (sv) 1997-04-09 1997-04-09 Astra Pharma Prod Compounds
JP2002509119A (ja) 1998-01-13 2002-03-26 アストラゼネカ ユーケイ リミテッド ドーパミン（Ｄ２）レセプターアゴニスト活性を有する化合物およびβ２−アドレナリンレセプターアゴニスト活性を有する化合物（Ｂ）を含有する薬学的組成物
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
SE9902935D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902936D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902937D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
SE9902938D0 (sv) 1999-08-18 1999-08-18 Astra Pharma Prod Pharmaceutical compositions
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
US6506901B2 (en) 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US7045658B2 (en) 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
EP1615881A2 (en) 2003-04-01 2006-01-18 Theravance, Inc. Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200526547A (en) 2003-09-22 2005-08-16 Theravance Inc Amino-substituted ethylamino β2 adrenergic receptor agonists
GB0324654D0 (en) 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
JP2005187357A (ja) 2003-12-25 2005-07-14 Nippon Suisan Kaisha Ltd 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
TW200531692A (en) 2004-01-12 2005-10-01 Theravance Inc Aryl aniline derivatives as β2 adrenergic receptor agonists
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
WO2005092861A1 (en) 2004-03-11 2005-10-06 Pfizer Limited Quinolinone derivatives pharmaceutical compositions containing them and their use
EP1577306A1 (de) 2004-03-17 2005-09-21 Boehringer Ingelheim Pharma GmbH & Co.KG Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
WO2005092841A1 (en) 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
CA2565243A1 (en) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituted benzo-condensed heterocycles for use as beta agonists in the treatment of respiratory diseases
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
DE102004024453A1 (de) 2004-05-14 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen
RU2006146042A (ru) 2004-06-03 2008-07-20 Тереванс Диаминные агонисты 2-адренергических рецепторов
JP2008507532A (ja) 2004-07-21 2008-03-13 セラヴァンス， インコーポレーテッド ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト
EP1778626A1 (en) 2004-08-16 2007-05-02 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
JP2008512470A (ja) 2004-09-10 2008-04-24 セラヴァンス， インコーポレーテッド アミジン置換アリールアニリン化合物
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
CN101137625A (zh) 2005-01-11 2008-03-05 葛兰素集团有限公司 β2肾上腺素能激动剂的肉桂酸盐
GB0511066D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
CN102051388B (zh) 2005-07-18 2013-03-27 辉瑞有限公司 化合物的制备方法
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200740781A (en) * 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
TW200745067A (en) 2006-03-14 2007-12-16 Astrazeneca Ab Novel compounds
WO2008041914A1 (en) 2006-10-06 2008-04-10 Astrazeneca Ab 5-(2-AMINO-L-HYDROXYETHYL)-8-HYDROXY-2-OXOQUINOLINE DERIVATIVES AND OTHER COMPOUNDS AS β2 -ADRENERGIC AGONISTS
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
US20120142646A1 (en) * 2006-12-20 2012-06-07 Lilian Alcaraz Novel Compounds 621
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0702459D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 669
GB0702458D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab Salts 668
GB0703999D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
WO2009037503A2 (en) 2007-09-18 2009-03-26 Astrazeneca Ab New combination - 012 for the treatment of respiratory diseases
JP2011524896A (ja) 2008-06-18 2011-09-08 アストラゼネカ・アクチエボラーグ 呼吸器障害の処置用のベータ２−アドレナリン受容体アゴニストとして作用するベンズオキサジノン誘導体
RU2011101664A (ru) 2008-06-20 2012-07-27 Астразенека Аб (Se) Фармацевтическая композиция, содержащая 4-гидрокси-2-оксо-2, 3-дигидро-1, 3-бензотиазол-7-ильное соединение, для модулирования активности бета2- адренорецепторов

Also Published As

Publication number Publication date
JP2011524896A (ja) 2011-09-08
AU2009260899A1 (en) 2009-12-23
EA201001747A1 (ru) 2011-08-30
CA2726746A1 (en) 2009-12-23
ZA201008886B (en) 2011-08-31
TW201002696A (en) 2010-01-16
US20100105642A1 (en) 2010-04-29
ECSP10010694A (es) 2011-01-31
DOP2010000389A (es) 2011-01-15
CN102124003A (zh) 2011-07-13
UY31905A (es) 2010-01-29
KR20110017456A (ko) 2011-02-21
MX2010013477A (es) 2010-12-21
EP2303873A1 (en) 2011-04-06
IL209731A0 (en) 2011-02-28
BRPI0915428A2 (pt) 2015-11-03
EP2303873A4 (en) 2012-01-04
AR072189A1 (es) 2010-08-11
AU2009260899B2 (en) 2012-02-23
CL2010001459A1 (es) 2011-09-23
WO2009154557A1 (en) 2009-12-23
CR11856A (es) 2011-02-25
US8017602B2 (en) 2011-09-13

Similar Documents

Publication Publication Date Title
CO6321269A2 (es) Derivados de benzoxazinona que actuan como agonistas de receptores adrenergicos beta 2 para el tratamiento de transtornos respiratorios
CO6260089A2 (es) Activadores de guanilato ciclasas solubles
CO5700757A2 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
ES2531056T3 (es) Espirociclos como inhibidores de 11-beta hidroxilesteroide deshidrogenasa tipo 1
CL2012001171A1 (es) Procedimiento para la preparacion del ester n-[[2-[[[4-[[[(hexiloxicarbonil)]4-amino]iminometil]fenil]amino]metil]1-alquil-1h-benzimidazol-5-il]carbonil]n-2-piridinil-etilico de beta-alanina; y uno de los compuestos intermediarios considerados.
AR068813A1 (es) Derivados de pirazol sustituidos como antagonistas del receptor de androgenos (ar), un agente farmaceutico que los comprende y su uso en el tratamiento del cancer de prostata
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
NO20092692L (no) MAPK/ERK kinaseinhibitorer
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
CO5700747A2 (es) Piperidinas novedosas como moduladores de quimoquina (ccr)
AR077975A1 (es) Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
PE20140934A1 (es) Derivados de pirazol
PE20110405A1 (es) Derivados de piridino-piridinonas como inhibidores de la actividad de la tirosina quinasa de pdgf-r y/o flt-3 y su preparacion
PE20090820A1 (es) Derivados de piperidina/piperazina
CR10034A (es) Derivados de oxadiazol
CR11245A (es) Mejoras en compuestos organicos o relacionadas con los mismos
GEP20135912B (en) 1-benzyl-3- hydroxymethylindazole derivatives and use thereat treatment of diseases based on mcp-1, cx3cr1 and p40 expression
UY29388A1 (es) Derivados del (1,5-difenil-h-pirazol-3-il)oxadiazol, su preparación y su aplicacion en terapéutica.
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
ES2421896T3 (es) Compuestos de aril-(imidazol)-metil-fenilo sustituidos como moduladores selectivos de los subtipos de receptores adrenérgicos alfa 2B y/o alfa 2C
IN2012DN00770A (es)
RS53414B (en) PIRAZINOOKSAZEPINA DERIVATIVES
AR062679A1 (es) Derivados de eter diarilico y usos de los mismos

Legal Events

Date Code Title Description
FA Application withdrawn